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Abstract
The utilisation of nanoparticles as the means of targeted delivery of therapeutics
and/or imaging agents could greatly enhance the specific transport of biologically
active payloads to target tissues while avoiding or reducing undesired side-effects.
To allow for this to become a reality, the question of potential toxicological effects
needs to be addressed. In the present investigation, a cationic liposome with
prospective for medical applications was constructed and thoroughly assessed for
any material-induced hepatic adverse effects in vivo − in healthy and alcoholic
hepatic disease models and in vitro − (HepG2 cells). The data demonstrated that
intravenous injection of liposomes did not cause any significant in vivo hepatic
toxicity (inflammation, alterations in blood parameters, anti-oxidant depletion,
acute phase response and histopathology) at doses of 200 μg per mouse in either
healthy or chronically alcohol fed mice. Additionally, the in vitro material-induced
adverse effects (cytotoxicity, inflammation or albumin secretion) were all also
minimal. The data from this study demonstrated that the intravenous injection of
cationic liposomes does not cause hepatic toxicity. This investigation is important
as it investigates the toxicity of a nano-sized material in a model of alcoholic
hepatic disease in vitro and in vivo. This is an area of research in the field of
nanotoxicology that is currently almost entirely overlooked.
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1. Introduction
Liposomes are biodegradable spherical vesicles composed of an aqueous core
surrounded by a phospholipid bilayer. These vesicles have been utilised as nano-
sized delivery vehicles for drugs, genetic material or imaging agents (Li et al.,
2015; Narayanaswamy et al., 2016). The encapsulation of relevant pharmaceutical
active compounds into liposomes can control the release thus reducing systemic
toxicity by minimizing dosage requirements (Bozzuto and Molinar, 2015). In
addition, liposomes can help to overcome biological barriers, which is necessary to
deliver the drug and exert the desired pharmacological effect. Due to their small
size, charge and the possibility for modification and inclusion of targeting moieties,
liposomes are ideal candidates for improved targeting and delivery efficiency
(Scott et al., 2008).
Nanomedicine is defined as the application and utilisation of nanotechnology to
medicine and human health, in particular with regards to the diagnosis and
treatment of disease. Over the last two decades a host of various nanomaterials
(NMs) with a wide range of physicochemical characteristics have been put forward
as having desirable properties (optical, electronic, magnetic and biological
attributes) for medical applications. Despite numerous promising new medical
functions in nanomedicine, the safety concern for NMs is a key determinant factor
for their clinical applications. It is imperative to establish structure-activity
relationships and implement risk reduction strategies for all materials proposed for
medical applications. In all reality, the same physicochemical characteristics that
make NMs desirable for medical applications might contribute to their potential
adverse effects (particle size and surface properties can largely influence the
bioavailability, transport, biotransformation and cellular uptake) (Nel et al., 2013;
Zhu et al., 2012). The importance of in vivo toxicological testing is further
underlined as following bodily distribution, NMs can undergo metabolic change
and/or protein coating/binding which could result in the formation of a material
that in all essence is very different with regards to how it interacts with its
biological surroundings in comparison the same material in vitro (Kermanizadeh
et al., 2015; Sareemaspun et al., 2008).
It has been demonstrated that the liver also has significance with regards to nano-sized
material accumulation and toxicity as it has been shown to preferentially accumulate
large quantities of these NMs following intravenous (IV) exposure compared to other
organs (Geraets et al., 2014; Kermanizadeh et al., 2015; Lipka et al., 2010; Sadauskas
et al., 2009) and alongside the kidneys might be responsible for the clearance of NMs
from the blood (Geiser and Kreyling, 2010; Semmler-Behnke et al., 2008). Similar to
other NMs, the IV administration of non-functionalised liposomes also results in large
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quantities of the materials accumulating in the liver (Belmadi et al., 2016; Dicheva
et al., 2016; Knudsen et al., 2014a). It is understood that global alcohol abuse was the
seventh leading cause of death in 2015, with 5.2% of the mortality worldwide
attributed to consumption of alcoholic beverages (Fulman et al., 2017). Additionally,
the excessive consumption of alcohol is a leading cause of chronic liver disease,
which results in a spectrum of disorders that range from simple fatty liver to more
severe forms of liver injury such as alcoholic hepatitis, cirrhosis, and hepatocellular
carcinoma affecting a large percentage of the general population which may or may
not present clinical manifestations of disease (Rocco et al., 2014; Zhu et al., 2014).
The liver is the principal organ for metabolising ethanol and thus considered as a
major target of the associate harmful effects (Bertola et al., 2013).
We have previously reported the manufacture and efficiency of an integrin-
modified positively charged liposome with great targeting potential for activated
endothelial cells found in inflammatory regions of injured vasculature (Kermani-
zadeh et al., 2017b). However, before any consideration for the utilisation of the
liposomes in medical settings, it is critical that the potential toxicological and
hazardous side-effects are thoroughly investigated. This is of absolute importance
with regards to hepatic toxicity as IV exposure is the principal mode of the
administration for these nanocarriers. In the present study, a wide range of end-
points (inflammation, alterations of bio-markers in blood, anti-oxidant depletion,
acute phase response and histopathology) linked to hepatic toxicity following
liposome exposure was investigated in vitro and in vivo both in healthy and in
alcohol disease models. Importantly, this is the one of the first studies of its kind to
consider or investigate nano-sized material-induced hepatic health effects in a
model which is representative of susceptible groups of the population; i.e.
individuals with pre-existing liver disease. This is an area of research in the field of
nanotoxicology that is almost entirely overlooked.
2. Materials and methods
2.1. Synthesis of the liposomes
The lipids 1,2-dioleoyl-sn-glycero-3-phoshocholine (DOPC) (Avanti Polar Lipids
Inc., USA), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-
sulfate (DOTAP) (Avanti Polar Lipids Inc., USA) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE)-Atto 655 (Thermo Fisher Scientific, UK) (molar
ratio − 9:1:0.002) were dissolved in chloroform and thoroughly mixed in a glass
vial. The solution was allowed to dry in order for a lipid film to form on the glass
and to ensure the complete evaporation of the solvent. The liposomes were
rehydrated by the addition of 1 x phosphate buffered saline (PBS), for a final lipid
concentration of 1 mg/ml. The mixture was incubated overnight at room
temperature. The following day, the liposomes were subjected to ten freeze-thaw
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cycles to minimize multilamellarity by immersion in liquid nitrogen followed by
thawing in a 40 °C water bath. The liposomes were then sequentially extruded
through two stacked polycarbonate filters with pore sizes of 50 nm (Mini-extruder
− Avanti Polar Lipids Inc., USA) and stored at 4 °C until use.
2.2. Characterisation of the liposomes
The hydrodynamic size distribution (Nanosight LM20, UK), stability and surface
charge of the liposomes (Zetasizer ZS, Malvern, UK) dispersed in filtered water,
PBS or complete cell culture medium as well as endotoxin content (LAL
PyrogentTM Plus assay, Lonza, Switzerland) has been reported previously
(Kermanizadeh et al., 2017b). A simplified version of [3_TD$DIFF]the data following of the
unonjugated liposomes in PBS and hepatocyte complete medium is presented
below.
2.3. Animals, diets and liposome treatments
Female C57BL/6 N mice (8 weeks, approximately 20 g) were obtained from
Taconic, Denmark. The mice were housed in polypropylene cages at controlled
environmental conditions as previously described (Kermanizadeh et al., 2017b).
The mice were fed on a regular mouse chow (Altromin 1324) for a period of 5 days
before being transferred to an all liquid diet (Lieber-DeCarli 82 rodent liquid diet,
control, Bio-Serv, USA) for a further 5 days. The mice were then divided into two
groups with one receiving the same liquid diet while the other group were fed an all
liquid diet supplemented with 5% ethanol (Lieber-DeCarli 82 rodent liquid diet,
ethanol, Bio-Serv, USA) for 25 days (Fig. 1).
Each animal received 20 ml of the liquid diet per day (fed every morning at the
same time). The nutritional information of the liquid diets is provided in Table 1.
The mice had free access to water through the feeding and liposome exposure
[(Fig._1)TD$FIG]
Fig. 1. The diagrammatic representation of the feeding schedule.
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period. The mice were weighed every 5 days during the feeding procedure as well
as on the day on which they were sacrificed. Following the feeding period, the
mice were anesthetized with isoflurane and exposed to 200 μg (100 μl) of
liposomes or by a single injection in the lateral tail (Table 2). The relatively large
dose was selected to account for a worst-case scenario in terms of potential acute
toxicity. The 168 h liposome exposure animals received the same ethanol or the
control liquid diet post material treatment. Following a 24 or 168 h exposure
period, the mice were anaesthetized (200 μl of ZFR cocktail − Zoletil 250 mg/ml,
Rompun 20 mg/ml and Fentanyl 50 μg/ml) and blood was collected form the heart
before the mice were sacrificed by exsanguination. The caudate lobe (glutathione
measurements) and the left lateral lobe (inflammation) of the liver were snap
frozen in liquid nitrogen and stored at −80 °C. Finally, the right medial lobe was
fixed in a 4% formaldehyde solution for histological analysis.
All animal experiments were conducted under the Danish federal guidelines for use
and care of laboratory animals (complied with the EC Directive 86/609/EEC) and
approved by the Danish animal inspectorate (licence number: 2012-15-2934-
00223).
Table 1. The nutritional profile of the two Lieber-Decarli 82 diets utilised in the
feeding schedule (Kcal/litre).
Component Control Ethanol
Protein 151 151
Fat 359 359
Carbohydrate 490 135
Ethanol + maltose dextrin 0 355
Table 2. The experimental design of the feeding and treatment groups.
Diet Treatment Time point Number of animals
Control PBS 24 h 5
Ethanol PBS 24 h 5
Control PBS 168 h 5
Ethanol PBS 168 h 5
Control liposomes 24 h 5
Ethanol liposomes 24 h 5
Control liposomes 168 h 5
Ethanol liposomes 168 h 5
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2.4. Blood biomarkers of liver damage
Intracardial blood samples were centrifuged to separate the serum and frozen at
−80 °C for the analysis of biomarkers and the acute phase response. The serum
samples were thawed and centrifuged for 10 min at 2,000 g at room temperature.
The supernatant was then used for the analyses of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), cholesterol, triglycerides and albumin
concentrations, performed on a Cobas 8000 modular analyser (Roche, USA).
2.5. Serum amyloid A3
The acute phase protein serum amyloid A3 (SAA3) was measured in serum
utilising a commercially available mouse SAA3 ELISA kit (Merck Millipore,
Denmark) according to the manufacturer’s instructions.
2.6. Inflammatory response
The liver samples were all thawed on ice, weighed and homogenised
(gentleMACSTM Dissociator − Miltenyi Biotec, Germany) in a homogenisation
buffer (PBS containing 1% Triton X–100 (Sigma, UK) containing a protease
inhibitor cocktail (104 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochlo-
ride, 80 μM of Aprotinin, 4 mM Bestatin, 1.4 mM E–64 mM, 2 mM Leupeptin and
1.5 mM Pepstatin A) (1:100) (Sigma, UK), pH 7.2, 4 °C). The samples were
thoroughly mixed (20 min) before centrifugation at 10,000 g for 10 min. The
supernatant was transferred to a fresh tube and centrifuged for a further 10 min
period (10,000 g). The levels of interleukin (IL) 1β, IL6, IL10, chemokine (C-X-C
motif) ligand 1 (CXCL1), and monocyte chemoattractant protein-1 (MCP-1)) in
the supernatant were assessed by flow cytometry (Accuri C6, BD Biosciences,
USA) using BDTM Cytometric Bead Array cytokine flex sets (bead based
immunoassay − BD Biosciences, USA).
2.7. Liposome-induced anti-oxidant depletion
The liver samples were weighed, thawed on ice and homogenized (as described
above) in 2 ml of lysis buffer (Senft et al., 2000) and incubated for 10 min before
being centrifuged at 10,000 g for 5 min to generate lysates. The reduced and total
glutathione was quantified in the lysate by reaction of sulfhydryl groups with the
fluorescent substrate o-phthalaldehyde (Sigma, UK) using a fluorometer with an
excitation wavelength of 350 nm and emission wavelength of 420 nm.
The total glutathione levels were evaluated by reducing oxidised glutathione
dimers (GSSG) to glutathione by the addition of 7 μl of 10 mM sodium dithionite
to all samples and incubation at room temperature for 1 h.
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2.8. Histology
The liver samples were trimmed, dehydrated and embedded in paraffin on a
Tissue-Tek VIP Jr. vacuum infiltration processor (Sakura, The Netherlands). The
dehydration step was followed by the clearing of samples in chloroform before the
sections were cut at 5 μm on a Shandon Finesse Microtome (Axlab, Denmark). The
sections were stained with haematoxylin and eosin (H&E staining) before
examination by light microscopy (Leica Microsystems, Germany).
2.9. In vitro ethanol and liposome treatment
The human hepatocellular carcinoma cell line (HepG2) (Sigma Aldrich, UK) was
maintained in Minimum Essential Medium Eagle (MEM) with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml Penicillin/Streptomycin and 1% non-
essential amino acids (all Sigma Aldrich, UK). On occasion and when required the
HepG2 cells were exposed to 50 mM of ethanol for 24 hr. The hepatocytes (104
cells per well (96 well Plates − TRP, Switzerland) in 100 μl of the cell culture
medium) were exposed to the liposomes in a concentration range between 0.62–39
μg/cm2 (equivalent to 2–125 μg/ml) for a further period of 24 hr.
2.10. WST-1 cell viability assay
Cell supernatants were removed; the wells were washed twice with PBS, followed
by the addition of 10 μl of the WST-1 cell proliferation reagent (Roche, USA) and
90 μl of fresh medium. The plates were then incubated for 1 h. The supernatant was
transferred to a fresh plate and the absorbance measured by dual wavelength
spectrophotometry at 450 nm and 630 nm using a micro-plate reader (Multiskan
FC − Thermo Scientific, USA) (supernatants were transferred to fresh plates in
order to decrease the potential interference of the materials during the
measurement).
2.11. In vitro production of IL8 and albumin
Following liposome treatment, cell supernatants were collected and frozen at −80
°C and later used for enzyme linked immunosorbent assays (ELISA). The
supernatants were centrifuged at 1,000 g and the cytokine and albumin levels
determined according to the manufacturer’s instructions (human IL8 ELISA kit −
Life Technologies, UK and human albumin ELISA kit − Bethyl laboratories,
USA).
2.12. Statistical analysis
The data is expressed as mean ± standard error of the mean (SEM). For statistical
analysis, the data was analysed by two-way full factorial ANOVA and post-hoc
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multiple comparisons (Tukey) with p < 0.05 as the level of statistical significance.
All statistical analysis was carried out utilizing Minitab 17 and Minitab Express.
3. Results
3.1. Characterisation of the liposomes
The characterisation data demonstrated that there was a tendency for the liposomes
to form small agglomerates (∼ 100 nm in PBS and ∼ 200 nm in complete medium).
However, the carriers were stable for at least three months after the initial extrusion
(Table 3). Additionally, no endotoxin contamination (≤ 0.25 EU/ml) was detected
in the suspension of liposomes.
3.2. In vivo data
3.2.1. Bodyweight changes in the alcohol fed and/or liposome
exposed mice
There was no significant change in the body weight of ethanol vs. control fed and
or liposome exposed mice (data not shown). In addition, no visible sign of
discomfort was noted in any of the mice during the feeding period or following the
liposome exposure.
3.2.2. Hepatic inflammation
The analysis of hepatic inflammation demonstrated that there was no obvious
liposome-induced effect at the time points and cytokines/chemokines investigated.
However, there was a significant and fairly large decrease in the levels of anti-
inflammatory IL10 in the alcohol fed mice as compared to the control liquid diet
fed mice (Fig. 2b). Interestingly, a time-dependent difference was noted in the
control diet fed and liposome exposed mice. However, these values were not
statistically significantly different from the appropriate PBS treated controls.
Furthermore, a significant increase in the levels of KC and MCP-1 was observed in
Table 3. The average mode and mean hydrodynamic size and zeta potential of the
liposomes dispersed in PBS and hepatocyte complete medium. Mode − the size
most abundant in the measurements. Mean − the average of the size in the
measurements. The data is presented as the average ± SEM (number of
independent experiments).
Mean (nm) Mode (nm) Zeta potential (mV)
PBS 117.3 ± 17 (6) 107.1 ± 22 (6) +21.9
Complete MEM 208.0 ± 57 (3) 185.4 ± 33 (3) Not tested
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the alcohol fed mice (Fig. 2a, c). The data clearly demonstrated an alcohol
stimulated disturbance to the normal “immune tolerant” milieu of the healthy liver.
No significant change in levels of hepatic specific IL1β or IL6 was detected for any
of the treatments and time-points investigated (IL1β − 0 pg/ml for the controls, all
treatments and time points; IL6 24 h − control-PBS 0.56 ± 0.4, ethanol-PBS 0.55
± 0.42, control-liposomes 0.09 ± 0.09, ethanol-liposomes 0.32 ± 0.2 pg/ml; IL6
168 h − control-PBS 0.23 ± 0.09, ethanol-PBS 0.1 ± 0.1, control-liposomes 0.05 ±
0.03, ethanol-liposomes 0.18 ± 0.13 pg/ml).
3.2.3. Blood biomarkers of liver damage
The analysis of blood biomarkers showed some statistically significant changes
which in majority were small with no discerning pattern observed. Unfortunately,
haemolysis in some samples affected the AST readings and resulted in fairly large
variations in these measurements. Overall the biochemical variables did not show
consistent evidence of liposome-induced toxicity to the liver (with the exception of
some fluctuations in the serum cholesterol levels however these were small and
inconsistent between the time-points) (Table 4). As expected the alcohol
consumption resulted in increased levels of AST and ALT in the blood (although
not statistically significant). The AST results findings should be considered with a
degree of caution because of haemolysis in some samples. Finally, time-dependent
differences were noted for several variables; however, no discriminating pattern
was observed between these alterations. It should be stated that previous studies
also show that chronic ethanol diets only result in mild changes in blood
biomarkers of liver toxicity (Bertola et al., 2013; Cohen et al., 2010; Mandrekar
et al., 2011). To that end, the lack of significant response is not all that surprising.
[(Fig._2)TD$FIG]
Fig. 2. Cytokine levels from control and alcohol fed mice livers following intravenous exposure of 200
μg of liposomes for 24 or 168 h. The values depict mean ± SEM (n = 5), significance indicated by □ =
p < 0.05 and □□ = p < 0.005, when indicative of an alcohol induced effect and αα = p < 0.005 when a
time-dependent effect is exhibited.
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Table 4. Liver toxicity blood bio-markers assessed in the serum of liposome exposed mice sacrificed 24/168 h post treatment. The values depict mean ±
SEM (n = 5), significance indicated by * = p < 0.05 and ** = p < 0.005, when indicative of an alcohol induced effect, ▽ = p < 0.05 and ▽▽ = p < 0.005
when a liposome-induced effect is observed. Interaction of alcohol and liposome effects signified by ⋄ = p < 0.05.
Biomarker of interest Control diet − PBS Ethanol diet − PBS Control diet − liposomes Ethanol diet − liposomes
ALT (U/l) − 24 h
- 168 h
23.52 ± 1.68 30 ± 2.85 25.44 ± 2.51 29.54 ± 6.37
30.26 ± 2.71 36.04 ± 4.83 24.12 ± 1.36 45.94 ± 9.87
AST (U/l) − 24 h ⋄
- 168 h
111 ± 23.3 187.3 ± 31.2 164.4 ± 17.1 118.7 ± 26.4
266.1 ± 40.4 178.6 ± 54.4 142.2 ± 37.9 162.3 ± 14.8
Albumin (g/l) − 24 h
- 168 h
12.38 ± 0.01 13.3 ± 0.33* 12.1 ± 0.11 12.38 ± 0.12▽
13.64 ± 0.19 13.26 ± 0.31 12.2 ± 0.22▽▽ 12.64 ± 0.27
Cholesterol (mmol/l) − 24 h ⋄
- 168 h ⋄
2.07 ± 0.08 2.08 ± 0.02 2.27 ± 0.06 1.94 ± 0.06*
1.98 ± 0.03 2.1 ± 0.1 1.96 ± 0.1 2.53 ± 0.08**▽▽
Triglycerides (mmol/l) − 24 h
- 168 h
0.82 ± 0.14 0.9 ± 0.16 0.68 ± 0.08▽ 0.76 ± 0.11
0.5 ± 0.03 0.64 ± 0.09 0.63 ± 0.08 0.67 ± 0.06
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3.2.4. Glutathione levels in the liver
As a measure of oxidative stress, reduced and total glutathione content were
quantified in the liver homogenates of the exposed mice (Fig. 3). The data
demonstrated that there was no significant difference in GSH levels following
either the alcohol or the liposome exposure at the two time-points investigated.
3.2.5. SAA3 concentrations in serum
The data indicated that there was a small (non-significant) increase in SAA3
concentrations in serum of the alcohol fed animals while, no liposome-induced
acute phase response was noted at either of the two time-points investigated
(Fig. 4).
3.2.6. Histology
The chronic alcohol consumption resulted in hepatic injury manifested most
notably as steatosis and slight necrosis (Fig. 5b). These findings were comparable
between the mice scarified at 24 and 168 h after liposome or vehicle exposure
(Table 5). The exposure to liposomes did not generate pathological effects in the
group of mice on alcohol-free control diet or the alcohol supplemented diet (with
the exception of a very few incidences of cytoplasmic degeneration in one of the
animals) (Table 5).
[(Fig._3)TD$FIG]
Fig. 3. The reduced (GSH) and total glutathione (Total GSH) measured in the livers of control and
ethanol fed animal exposed to 200 μg of liposomes at 24 and 168 h. The values depict mean ± SEM (n
= 5).
Article No~e00458
11 http://dx.doi.org/10.1016/j.heliyon.2017.e00458
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
3.3. In vitro data
3.3.1. Impact of liposome exposure on HepG2 cell cytotoxicity
From the WST-1 data it was evident that there was very little cytotoxicity
associated with liposome exposure even at concentrations up to 39 μg/cm2. That
being said a significant difference could be observed between the ethanol pre-
treated hepatocytes and the controls at the five highest concentrations (Fig. 6). The
data showed that ethanol pre-treated cells are more susceptible to cytotoxicity by
co-exposure to liposomes.
3.3.2. Impact of liposome exposure on HepG2 IL8 production
The changes in cytokine secretion as a consequence of liposome exposure was
assessed in the supernatant of exposed hepatocytes and quantified via ELISA. The
data demonstrated no effect of liposome exposure on the levels of the chemokine
secreted from the cells. In addition, alcohol pre-treatments seemed to have no
significant effect on this end-point (Fig. 7).
3.3.3. Impact of the liposome exposure on albumin levels in
HepG2 cells
Albumin levels were measured as a marker of hepatocyte function in ethanol and/
or liposome treated cells. The data showed no effect of either ethanol pre-treatment
or liposome exposure on albumin secretion from the hepatocytes at the
concentrations investigated (Fig. 8).
[(Fig._4)TD$FIG]
Fig. 4. SAA3 measured in the serum of control and ethanol fed animal exposed to 200 μg of liposomes
for 24 or 168 h. The values depict mean ± SEM (n = 5).
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[(Fig._5)TD$FIG]
Fig. 5. The histopathological examination of H&E stained liver tissue from a) mice on control diet, b)
mice on the alcohol supplemented diet. Foci with steatosis and slight necrosis are present in the image
from alcohol exposed mice, whereas the architecture of the liver is normal in the image of the mouse
from the control diet group. The images are representative for each of the groups of 3 mice investigated.
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4. Discussion
In this study, we demonstrate that the cationic liposome nanocarriers, which are
prime candidates for utilisation in medical applications, induced no adverse effects
to hepatocytes in vitro at concentrations of up 39 μg/cm2. Additionally, IV
exposure of liposomes did not cause any significant hepatic toxicity in vivo at
doses of up to 200 μg per mouse either in healthy or chronically alcohol fed mice.
This study is important as it sets the foundations for future in vivo exploitation of
the carriers as it is one of the first studies to investigate nano-sized liposome
toxicity in models of alcoholic hepatic disease in vitro and in vivo.
Table 5. The histological score of liver pathology from three slides from three random animals for each
treatment group ranked from 0–5 (none to severe).
24 h Control diet − PBS Ethanol diet − PBS Control diet − liposomes Ethanol diet − liposomes
Steotosis 0, 0, 0 4, 4, 3 0, 0, 0 3, 3, 4
Inflammation 0, 0, 0 0, 0, 1 1, 1, 1 1, 0, 1
Necrosis 0, 0, 0 0, 1, 0 0, 0, 0 0, 0, 0
168 h Control diet − PBS Ethanol diet − PBS Control diet − liposome Ethanol diet − liposome
Steotosis 0, 0, 0 5, 5, 5 0, 1, 0 4, 5, 5
Inflammation 0, 0, 0 0, 1, 0 1, 0, 1 0, 1, 1
Necrosis 0, 0, 0 0, 1, 1 0, 0, 0 1, 0, 0
[(Fig._6)TD$FIG]
Fig. 6. Cytotoxicity in control and ethanol (50 mM) pre-treated HepG2 cells following exposure to
cationic liposomes. The cells were exposed to cell medium (control)/increasing concentrations of the
liposomes for 24 h with cytotoxicity measured via WST-1 assay. The values represent mean ± SEM (n
= 3 − three separate days), significance between the groups indicated by * = p < 0.05.
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In this study, almost all hepatic adverse effects investigated (changes in the
inflammatory profile in the liver, alteration in blood bio-markers and histopatho-
logical observations in terms of moderate fatty changes (steatosis)) were induced
by the chronic alcohol feeding of animals. Similar findings have previously been
reported in alcohol fed animals (albeit different feeding periods/alcohol
concentrations/different combination of end-point investigated) (Anthony et al.,
2010; Ki et al., 2010; Rhodes et al., 2005). However, there was no evidence that
liposome exposure results in any significant adversity in the liver of healthy
[(Fig._7)TD$FIG]
Fig. 7. IL8 secretion within HepG2 cell supernatants following a 24 h exposure period to increasing
concentrations of the liposomes. The values represent mean ± SEM (n = 3 − three separate days).
[(Fig._8)TD$FIG]
Fig. 8. Albumin production from non and pre-ethanol treated HepG2 cells following exposure to
increasing concentrations of the liposomes. The cells were exposed to medium (control) or the
liposomes for 24 h. The values represent mean ± SEM (n = 3 − three separate days).
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animals or caused intensification of disease in the alcohol fed animals at either
time-point investigated. The data from this study fits very well with our previous
findings in which very little toxicity (measured in terms of mitochondrial function
and inflammatory response) was observed in vitro following liposome treatment of
mono-cultured endothelial cells and co-cultures of endothelial cells and
macrophages (Kermanizadeh et al., 2017b). It should be noted that our animal
model was able to detect adverse effects of silver NM exposure on most of the
measured end-points and was aggravated by prior alcohol exposure (Kermanizadeh
et al., 2017a).
In concordance to the findings within this study the principal body of in vitro and
in vivo investigations into toxicity associated with empty cationic liposome
exposure have also demonstrated the adverse effects to be very limited and
restricted to high non-physiologically relevant doses/concentrations. As some
examples, the effects of cationic liposome delivery systems (∼ 100 nm DOTAP/
cholesterol) were investigated in vitro in A549 and HepG2 cell lines (cytotoxicity,
lipid accumulation, genotoxicity and secretion of pro-inflammatory cytokines) and
in vivo (Han Wistar rats intravenously exposed to the liposomes at doses of 10, 25
or 100 mg/kg with analysis of blood bio-markers, histopathology and genotoxicity)
(Knudsen et al., 2015; Roursgaard et al., 2016). The authors showed that,
liposome-induced toxicity was only limited to concentrations above 100 μg/ml in
A549 and HepG2 cells (Roursgaard et al., 2016). The study of the in vivo toxicity
effects only demonstrated very limited effects of liposome administration − in
terms of histopathology and clinical chemistry (Knudsen et al., 2015). Similarly,
the repeated IV administration of the same liposome at doses of 100 mg/kg on
three separate occasions over a period of a week was well tolerated and not
associated with any systemic toxicity (Knudsen et al., 2014b). However, it should
be stated that cationic liposome toxicity has been observed in in vitro settings with
cell type being an important determinant of the adverse effects detected; i.e.
macrophages are highly susceptible to cytotoxic effects of liposome exposure − in
all probability due to high uptake by these professional phagocytes (Iwaoka et al.,
2006; Nogueira et al., 2013; Romoren et al., 2004; Xia et al., 2008).
Alcohol abuse can have an impact not only on the incidence of disease (most
prominently liver cirrhosis), but also on the progression of disorders; making
alcohol-attributable disease a major factor in global burden of health corollaries
(Rehm and Shield, 2013). There is extensive variation in the total alcohol
consumption globally and even a wider spectrum of adverse effect associated with
alcohol abuse, meaning that a large percentage of the overall population could be
suffering from unregistered sub-clinical symptoms. Therefore, it is crucial that this
large and vulnerable sub-group of the general population is included in any hazard
and risk assessment strategy. In this study, we show that our liposomes do not have
any adverse health effects in alcohol damaged liver or ethanol exposed hepatocytes
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as models of susceptibility to liver cirrhosis. This is one of the only two
nanotoxicological studies to include this important variable in the hazard
assessment of materials utilising a life-style relevant material, dose and route of
exposure.
Currently, the majority of the research in the field of nanomedicine is focused on
the application of NMs with relatively little attention paid to the potential
toxicological consequences. As a corollary, the systematic toxicological evaluation
of NMs is often not ruminated during the product development process. It is
extremely important to fully consider the ramifications of the utilisation of unique
exposure routes in nanomedicine that intentionally bypass the normal absorption
processes which might be a cause of real concern with regards to systemic
material-induced toxicity. Therefore, it is imperative that a wide range of toxicity
and relatable end-points with appropriate doses is investigated for safe design and
utilisation of nano-constructs for medical applications. In this study, we show the
production of highly reproducible stable liposomes with very little toxic potential
both in vitro and in healthy or in alcohol-exposed animals (as a representative
model of individuals in general population with pre-existing hepatic medical
complications).
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